In the first half of 2018 JLLC «Lekpharm» expanded the capabilities of doctors in the treatment of patients with cardiovascular diseases, mastering the release of drugs from the new class - antagonists of angiotensin II receptors (sartans). The novelty is presented in the form of a fixed combination of Losartan Plus (losartan / hydrochlorothiazide), is available in three dosages of 50 mg / 12.5 mg, 100 / 12.5 mg, 100/25 mg, as tablets coated with a coating, No. 30.
Losartan Plus is the only domestic fixed combination of losartan and hydrochlorothiazide. The combination of two drugs with different mechanisms of action in one Lozartan Plus tablet and convenient administration once a day makes it possible to greatly simplify the therapy of patients with arterial hypertension who need combination therapy.